DMI BioSciences, Inc. Retains Goldblum Lentz & Co.Business Editors/Health & Medical Writers BIOWIRE2K ENGLEWOOD, Colo.--(BW HealthWire)--Sept. 13, 2000 DMI (Desktop Management Interface) The first desktop management standard from the DMTF. Enabling PCs to be monitored from a central console, it was superseded by the DMTF's Common Information Model (see CIM). BioSciences, Inc. today announced it has entered into an agreement with Goldblum Lentz & Co. for that firm to act in an advisory capacity to DMI in the selection of a major investment banking firm to act as placement agent for the company in securing an estimated $20 - $40 million in private equity funding Equity funding An investment consisting of a life insurance policy and a mutual fund. The insurance policy is paid by the collateral value of fund shares, giving the investor the advantages of insurance protection with the growth potential of a mutual fund. with institutional investment sources and/or designated strategic corporate investors. DMI is presently in discussions with a number of "Tier 1" investment firms relative to its corporate finance needs to support its research and the further development and ultimate commercialization of some very promising pharmaceutical and diagnostic products. "Goldblum Lentz's experience and solid working understanding of the Wall Street investment banking environment will be of great assistance to us in selecting and negotiating with the investment banking firm that will best serve our corporate finance needs in the public and private capital markets," said Bruce G. Miller, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of DMI. "After discussions with a number of firms capable of acting in an advisory capacity to us, we selected Goldblum Lentz & Co. based on their relationships and experience with a number of the investment banking firms with whom we are presently in discussions. In addition, the management team at DMI very quickly established a good rapport with Goldblum Lentz, which, combined with their local presence, made our selection an easy one," said Miller. "Our decision to accept the engagement by DMI is based upon our evaluation of the prospect of the company being able to attract the investment capital it needs to advance its substantial product pipeline. We look forward to a fruitful relationship," said David Goldblum, president of Goldblum Lentz. DMI is a development stage biopharmaceutical company focused on the development of therapeutics that address significant unmet medical needs and conditions. DMI's discovery and technology platform, called the "Accelerated Biological Discovery System(TM)" (ABDS ABDS Accounting & Budget Distribution System ABDS Atherstone Binge Drinking Society (Facebook group) (TM)) is based upon the company's discovery of a general process of the body that seems applicable to many diseases. "The ABDS represents the `industrialization' of discovery within a general biochemical process that can be applied to a disease state in a modular form. Components of the process can be changed based on the target organ target organ n. A tissue or organ that is affected by a specific hormone. target organ, n the organ or body part whose activity levels demonstrate change in the course of biofeedback. , disease or specific molecule involved," according to David Bar-Or, chairman and chief scientific officer of the company. The purpose of the ABDS is to generate very high-quality, disease specific targets and potential drugs in a very rapid and cost-effective manner. This is accomplished by providing a clear and repeatable method for the rapid modification and analysis of well-characterized proteins and peptides that have been clearly implicated im·pli·cate tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates 1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot. 2. in significant human diseases. Future refinements include integration of the ADBS ADBS Association des Professionnels de l'Information et de la Documentation ADBS All Day Breakfast Show (podcast) ADBS Advanced Data Broadcasting System ADBS Action Driven Balanced Scorecard with genomic and proteomic databases in order to increase the number of levels at which therapeutic interventions may occur. This $20M to $40M funding will enable the company to advance potential therapeutics for cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease (initially for low cardiac output cardiac output n. Abbr. CO The volume of blood pumped from the right or left ventricle in one minute. It is equal to the stroke volume multiplied by the heart rate. syndrome, or heart stunning), diabetes, Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , and possibly prostate cancer or breast cancer. "With this funding we hope to be able to get two drugs into clinical trials within the next 24 to 36 months, and to potentially have two very significant diagnostic products on the market," according to Gary S. Held, the company's chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . "At that point in time we will look to the investment banking relationships we are presently establishing with the help of Goldblum Lentz to provide the access to public and/or private capital markets as may be necessary or advisable." DMI BioSciences, Inc. is a Colorado corporation formed in 1990 as Diagnostic Markers, Inc., with offices and discovery laboratories in Englewood, Colorado, and with development laboratories in the United Kingdom. DMI and its wholly owned subsidiaries employ 26 people in the United States and the U.K. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion